By Deena Beasley Dec 12 (Reuters) - Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite ...

Lululemon Athletica (LULU) to exit the Nasdaq 100 as part of the gauge's annual shakeup, with Seagate (STX) and five others ...

Biogen (BIIB) stock slips as HSBC downgrades to a Sell equivalent rating as part of an analysis that included an upgrade on ...

Biogen's fair value estimate has nudged higher to about $178.76 per share, even as its discount rate ticks up slightly to roughly 7.49 %, signaling a modestly higher perceived risk backdrop. The shift ...

Analysts at Jefferies see blockbuster potential in zorevunersen in Dravet syndrome, with sales potentially reaching $1 ...

New analyses from the ongoing open label extension (OLE) studies and findings from electroencephalogram (EEG) assessments in ...

Strategy stock maintains Nasdaq 100 inclusion after rebalancing while MSCI reviews digital asset treasury companies. Decision ...

Zurzuvae was generally well-tolerated, with the most common side effects being sedation, somnolence and dizziness.

Bitcoin giant Strategy kept its spot in the Nasdaq 100 on Friday, holding its year-long run inside the index while debate ...

Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines ...

Biogen (BIIB) shares have been actively discussed lately, as some investors weigh the stock's longer-term track record against recent performance. Over the past month, Biogen stock has climbed by 15%, ...